Clinical Trials Logo

Filter by:
NCT ID: NCT03891329 Completed - Heart Failure Clinical Trials

Master Study of the Acticor/Rivacor ICDs/CRT-Ds and the Plexa ProMRI S DX Lead

Start date: April 30, 2019
Phase: N/A
Study type: Interventional

Post-Market Clinical Follow-up of the new Cor Family ICDs/CRT-Ds (Acticor, Rivacor) and the new Plexa ProMRI S DX right ventricular lead to provide post-market data and supporting evidence for the clinical safety and performance of the devices.

NCT ID: NCT03890809 Completed - Healthy Volunteers Clinical Trials

An Investigational Study of BMS-986165 in Participants With Normal Liver Function and Participants With Mild to Severe Liver Damage

Start date: February 26, 2019
Phase: Phase 1
Study type: Interventional

The purpose of this study is to investigate BMS-986165 in participants with different levels of liver function.

NCT ID: NCT03890770 Completed - Healthy Volunteer Clinical Trials

A Study to Assess the Safety of Experimental Medication BMS986165 in Participants With Normal Kidney Function and Participants With Mild to End-Stage Kidney Disease.

Start date: April 4, 2019
Phase: Phase 1
Study type: Interventional

The purpose of this study is to investigate BMS-986165 in participants with different levels of kidney function.

NCT ID: NCT03888066 Completed - Hyperkalemia Clinical Trials

Patiromer for the Management of Hyperkalemia in Subjects Receiving RAASi Medications for the Treatment of Heart Failure (DIAMOND)

DIAMOND
Start date: April 24, 2019
Phase: Phase 3
Study type: Interventional

The purpose of this study is to assess the effects of patiromer compared with placebo on serum K+ in HF patients.

NCT ID: NCT03887520 Completed - Clinical trials for Cardiovascular Disease and Lipoprotein(a)

Lipoprotein(a) in Patients With Cardiovascular Disease (CVD)

Start date: November 27, 2018
Phase: N/A
Study type: Interventional

The study is conducted to improve knowledge about the epidemiology of Lipoprotein(a) in patients with established cardiovascular disease (CVD).

NCT ID: NCT03882970 Completed - Clinical trials for Type 2 Diabetes Mellitus

A Study of Tirzepatide (LY3298176) Versus Insulin Degludec in Participants With Type 2 Diabetes

SURPASS-3
Start date: April 1, 2019
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare the effect of the study drug tirzepatide to insulin degludec on blood sugar levels in participants with type 2 diabetes. The study will last about 67 weeks and may include up to 22 visits.

NCT ID: NCT03881059 Completed - Clinical trials for Active Psoriatic Arthritis

Efficacy and Safety of BMS-986165 Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA)

Start date: April 1, 2019
Phase: Phase 2
Study type: Interventional

The main purpose of study is to assess the dose-response relationship of BMS-986165 (Dose A or Dose B once daily [QD]) at Week 16 in the treatment of participants with active PsA.

NCT ID: NCT03875729 Completed - Clinical trials for Type 1 Diabetes Mellitus

Recent-Onset Type 1 Diabetes Trial Evaluating Efficacy and Safety of Teplizumab

PROTECT
Start date: April 5, 2019
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine whether teplizumab slows the loss of β cells and preserves β cell function in children and adolescent 8-17 years old who have been diagnosed with T1D in the previous 6 weeks.. Subjects will receive two courses of either teplizumab or placebo treatment 6 months apart.

NCT ID: NCT03873974 Completed - Lyme Borreliosis Clinical Trials

Performance Evaluation of the DualDur In Vitro Diagnostic System in the Diagnosis of Lyme Borreliosis

Start date: July 2, 2019
Phase:
Study type: Observational

The clinical data from the clinical trial will be used to assess the performance, sensitivity and specificity of the experimental DualDur In Vitro Diagnostic System.

NCT ID: NCT03866759 Completed - HIV Infections Clinical Trials

Prospective Observational Cohort HIV & STI Study in Europe

Start date: April 24, 2019
Phase:
Study type: Observational

The University Hospital Essen is sponsoring the Multicenter human immunodeficiency virus (HIV) and sexually transmitted infections Prevention Network Study (STIPnet) which is funded by Janssen, Pharmaceutical Companies of Johnson & Johnson. STIPnet study is a prospective observational cohort study aiming to determine the incidence and point prevalence of HIV infection and the most common sexually transmitted infections (STIs) in individuals with sexual risk behavior. In addition, the University Hospital Essen will examine whether individuals at risk for HIV and STI infections would retain in such a study (retention rate) and would be willing to participate in potential HIV and STI prevention trials (willingness to participate).